← Browse by Condition
Medical Condition
primary myelofibrosis
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 3
ClinicalMetric tracks all active clinical trials for primary myelofibrosis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — primary myelofibrosis Clinical Trials
How many clinical trials are currently recruiting for primary myelofibrosis?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for primary myelofibrosis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for primary myelofibrosis?
primary myelofibrosis research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a primary myelofibrosis clinical trial?
Eligibility criteria for primary myelofibrosis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 1
Phase 2 2
Phase 3 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06517875 Phase 2
Recruiting
Enrollment
68 pts
Location
United States, Canad...
Sponsor
GlaxoSmithKline
NCT06073847
Recruiting
Enrollment
137 pts
Location
South Korea
Sponsor
Bristol-Myers Squibb
NCT06327100 Phase 1, Phase 2
Recruiting
Enrollment
33 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT02760238
Recruiting
Enrollment
5,000 pts
Location
Canada
Sponsor
University Health Network, Tor...
NCT06468033 Phase 3
Recruiting
Enrollment
150 pts
Location
Japan
Sponsor
PharmaEssentia
NCT06351631 Phase 3
Recruiting
Enrollment
400 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC
NCT02897297
Recruiting
Enrollment
1,000 pts
Location
France
Sponsor
University Hospital, Brest
Related Conditions
post polycythemia vera myelofibrosis (3) polycythemia vera (3) post essential thrombocythemia myelofibrosis (2) essential thrombocythemia (2) myelofibrosis primary myelofibrosis post polycythemia vera myelofibrosis post essential thrombocythemia myelofibrosis (1) post essential thrombocytosis myelofibrosis (1) mastocytosis (1) leukemia myeloid chronic atypical bcr abl negative (1) leukemia myelomonocytic juvenile (1) chronic eosinophilic leukemia not otherwise specified (1) myelodysplastic myeloproliferative diseases (1) neoplasms (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology